Study Evaluation Rentosertib (INS018_055) Administered Orally in Patients With Idiopathic Pulmonary Fibrosis (IPF)
A Prospective Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Study Evaluating the Efficacy and Safety of Rentosertib (INS018_055) Administered Orally Over 52 Weeks in Patients With Idiopathic Pulmonary Fibrosis (IPF)
This is a multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of Rentosertib (INS018_055) administered orally in Patients with Idiopathic Pulmonary Fibrosis.
The purpose of this study is to evaluate if Rentosertib (INS018_055) works to treat patients with Idiopathic Pulmonary Fibrosis in adults. It will also learn about the safety of Rentosertib (INS018_055).
In this study, Rentosertib (INS018_055) will be compared to a placebo (a look-alike substance that contains no drug) to investigate if Rentosertib (INS018_055) works to treat Idiopathic Pulmonary Fibrosis.
研究概览
研究类型
注册 (估计的)
阶段
- 第三阶段
联系人和位置
学习联系方式
- 姓名:Qinhan Chen
- 电话号码:+86 021-50831718
- 邮箱:Insilico-Clinicaltrial@insilico.ai
学习地点
-
-
Anhui
-
Hefei、Anhui、中国
- 尚未招聘
- Anhui Provincial Hospital
-
Hefei、Anhui、中国
- 尚未招聘
- Anhui Chest Hospital
-
-
Beijing Municipality
-
Beijing、Beijing Municipality、中国
- 招聘中
- Peking Union Medical College Hospital
-
Beijing、Beijing Municipality、中国
- 招聘中
- Beijing Friendship hospital, Capital Medical University
-
Beijing、Beijing Municipality、中国
- 尚未招聘
- Beijing Chaoyang Hospital, Capital Medical University
-
-
Fujian
-
Fuzhou、Fujian、中国
- 尚未招聘
- Fuzhou University Affiliated Provincial Hospital
-
Xiamen、Fujian、中国
- 招聘中
- The Second Affiliated Hospital of Xiamen Medical College
-
-
Guangdong
-
Guangzhou、Guangdong、中国
- 招聘中
- The First Affiliated Hospital of Guangzhou Medical University
-
Guangzhou、Guangdong、中国
- 尚未招聘
- Nanfang Hospital, Southern Medical University
-
-
Guangxi
-
Nanning、Guangxi、中国
- 尚未招聘
- The First Affiliated Hospital of Guangxi Medical University
-
-
Hainan
-
Haikou、Hainan、中国
- 招聘中
- Hainan General Hospital
-
-
Hebei
-
Shijiazhuang、Hebei、中国
- 尚未招聘
- The Second Hospital of Hebei Medical University
-
Shijiazhuang、Hebei、中国
- 尚未招聘
- Hebei Medical University Third Hospital
-
-
Henan
-
Anyang、Henan、中国
- 招聘中
- The People's Hospital of Anyang City
-
Nanyang、Henan、中国
- 招聘中
- Nanyang First People's Hospital
-
Zhengzhou、Henan、中国
- 尚未招聘
- Henan Provincial People's Hospital
-
Zhengzhou、Henan、中国
- 尚未招聘
- The First Affiliated Hospital of Zhengzhou University
-
-
Hubei
-
Wuhan、Hubei、中国
- 尚未招聘
- Renmin Hospital of Wuhan University
-
Wuhan、Hubei、中国
- 尚未招聘
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
-
Yichang、Hubei、中国
- 尚未招聘
- Yichang Central People's Hospital
-
-
Hunan
-
Changsha、Hunan、中国
- 尚未招聘
- The Second Xiangya Hospital of Central South University
-
Changsha、Hunan、中国
- 尚未招聘
- The Xiangya Hospital of Central South University
-
-
Inner Mongolia
-
Hohhot、Inner Mongolia、中国
- 尚未招聘
- The Affiliated Hospital of Inner Mongolia Medical University
-
-
Jiangsu
-
Nanjing、Jiangsu、中国
- 招聘中
- Nanjing Drum Tower Hospital
-
Xuzhou、Jiangsu、中国
- 尚未招聘
- The Affiliated Hospital of Xuzhou Medical University
-
-
Jiangxi
-
Nanchang、Jiangxi、中国
- 尚未招聘
- Jiangxi Provincial People' Hospital
-
-
Jilin
-
Changchun、Jilin、中国
- 尚未招聘
- The Second Hospital of Jilin University
-
-
Liaoning
-
Shenyang、Liaoning、中国
- 尚未招聘
- Shengjing Hospital of China Medical University
-
-
Shaanxi
-
Xi'an、Shaanxi、中国
- 招聘中
- The Second Affiliated Hospital of Xi'an Jiaotong University
-
Xi'an、Shaanxi、中国
- 招聘中
- The First Affiliated Hospital of Xi'an Medical College
-
-
Shandong
-
Jinan、Shandong、中国
- 尚未招聘
- Qilu Hospital of Shandong University
-
Jinan、Shandong、中国
- 尚未招聘
- Introduction of the First Affiliated Hospital of Shandong First Medical University
-
-
Shanghai Municipality
-
Shanghai、Shanghai Municipality、中国
- 招聘中
- Shanghai Pulmonary Hospital Affiliated to Tongji University
-
-
Shanxi
-
Taiyuan、Shanxi、中国
- 尚未招聘
- Shanxi Bethune Hospital
-
Yuncheng、Shanxi、中国
- 尚未招聘
- Yuncheng Central Hospital
-
-
Sichuan
-
Chengdu、Sichuan、中国
- 尚未招聘
- West China Hospital, Sichuan University
-
Chengdu、Sichuan、中国
- 尚未招聘
- Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital
-
-
Tianjin Municipality
-
Tianjin、Tianjin Municipality、中国
- 尚未招聘
- Tianjin Medical University General Hospital
-
Tianjin、Tianjin Municipality、中国
- 尚未招聘
- Tianjin Chest Hospital
-
-
Xinjiang
-
Ürümqi、Xinjiang、中国
- 尚未招聘
- The First Affiliated Hospital of Xinjiang Medical University
-
-
Yunnan
-
Kunming、Yunnan、中国
- 尚未招聘
- The First People Hospital of Yunnan Province
-
-
Zhejiang
-
Hangzhou、Zhejiang、中国
- 尚未招聘
- Sir Run Run Shaw Hospital Zhejiang University School of Medicine
-
Hangzhou、Zhejiang、中国
- 招聘中
- Affiliated Hangzhou First People's Hospital,School of Medicine, Westlake University
-
Jiaxing、Zhejiang、中国
- 尚未招聘
- The First Hospital of Jiaxing
-
Ningbo、Zhejiang、中国
- 尚未招聘
- Ningbo Medical Center Lihuili Hospital
-
Ningbo、Zhejiang、中国
- 尚未招聘
- The First Affiliated Hospital of Ningbo University
-
Wenzhou、Zhejiang、中国
- 尚未招聘
- The First Affiliated Hospital of Wenzhou Medical University
-
-
参与标准
资格标准
适合学习的年龄
- 成人
- 年长者
接受健康志愿者
描述
Inclusion Criteria:
- An informed consent form (ICF) signed and dated at screening (Visit 1), prior to initiation of any study related procedures, and in accordance with ICH-GCP and local legislation.
- Patients aged ≥40 years at time of signing the ICF.
- Diagnosis of IPF based on the 2022 ATS/ERS/JRS/ALAT Clinical Practice Guideline, confirmed by an HRCT chest scan within 3 months prior to screening visit.
- UIP or probable UIP with fibrosis extent >10% at HRCT.
Meet all the following criteria during the screening period:
- FVC ≥45% predicted of normal
- FEV1/FVC ≥0.7
- DLCO (corrected for hemoglobin) ≥25% and <80% predicted of normal.
Background antifibrotic therapies are allowed, patients may be either:
- on a stable therapy with nintedanib or pirfenidone as monotherapy for at least 12 weeks prior to screening visit and during the screening period and are planning to stay on this background treatment after randomization.
- not on a treatment with nintedanib or pirfenidone for at least 8 weeks prior to screening visit and during the screening period and do not plan to start or restart antifibrotic therapy.
- Estimated minimum life expectancy of at least 30 months for non-IPF related disease in the opinion of the investigator.
- Male patients and female patients of childbearing potential agree to use highly effective contraception/preventive exposure measures from the time of the first dose of the study drug (for the male patient) or the signing of the ICF (for the female patient) until 90 days after the last dose of the study drug.
Exclusion criteria:
- Interstitial lung disease associated with known primary diseases (eg, autoimmune disease-related interstitial lung diseases, sarcoidosis and amyloidosis), exposures (eg, radiation, silica, asbestos, and coal dust), or drugs (eg, amiodarone).
- Previous participation in a clinical study with rentosertib (active or placebo).
- Concurrent participation in another interventional drug, device, or biological investigational research study, or use of an investigational agent within 5 half-lives of the agent (or within 8 weeks when half-life is unknown) prior to screening is not allowed.
- Pulmonary hypertension that is clinically relevant or severe as deemed by the investigator, or other clinically significant pulmonary abnormalities.
- Unstable cardiovascular or other disease within 6 months prior to the screening visit or during the screening period.
- Presence of other clinically significant airway disease that may, in the opinion of the investigator, impact the study safety or efficacy objectives, such as asthma, bronchiectasis, cystic fibrosis, active aspergillosis, active tuberculosis, or other serious concomitant respiratory disorder other than pulmonary fibrosis.
- Acute exacerbation of IPF within 6 months prior to screening visit and/or during the screening period.
- Patients with underlying chronic liver disease (Child Pugh A, B, or C hepatic impairment), hepatic steatosis (including non-alcoholic steatohepatitis and/or other types of fatty liver diseases).
- Patients with Gilbert's disease
- Relevant chronic or acute infections including human immunodeficiency virus (HIV) and clinically significant viral hepatitis.
- Aspartate aminotransferase or alanine aminotransferase ≥1.5 × upper limit of normal (ULN), and/or total bilirubin ≥1.5 × ULN, and/or gamma glutamyl transferase ≥3 × ULN, and/or alkaline phosphatase ≥1.5 × ULN at screening.
- Estimated glomerular filtration rate <60 mL/min/1.73m2 at screening.
- Patient with 12-lead ECG demonstrating corrected QT interval by Fridericia (QTcF) >450 ms for males and >470 ms for females at screening (Visit 1).
- Patient with a history of lung volume reduction surgery or lung transplant.
- Current smoker and/or cotinine (smoking) test positive.
- History of drug abuse, drug use, or alcohol abuse within the past 3 months.
- Major surgery performed within 3 months prior to screening visit, during the screening period, or have major surgery planned during the study period.
- Any documented active or suspected malignancy or history of malignancy within 5 years prior to screening visit.
- Use of any of the following therapies within 4 weeks prior to screening visit and during the screening period or planned during the study: warfarin and immunosuppressive medications.
- Patients currently taking endothelin receptor antagonists,phosphodiesterase type 5 inhibitors, soluble guanylate cyclase modulators, prostacyclin analogues and prostanoids, or activin signaling inhibitor.
- Patients currently on a treatment with nerandomilast within 8 weeks prior to screening visit and during the screening period.
Use of any of the following drugs within 2 weeks prior to Visit 1/screening or planned during the duration of the study
- Strong and moderate cytochrome P450 3A4 or 1A2 inhibitors/inducers
- Medications associated with substantial risk for prolongation of corrected QT interval.
- Patients who have consumed grapefruit or grapefruit juice, pomelo, Seville orange or Seville orange-containing products within 48 hours before Day 1.
- Patients who used hormone replacement therapy in the 4 weeks prior to randomization. No hormone replacement therapy use is allowed during the study.
- Patients with known hypersensitivity or contraindications to serine/threonine kinase inhibitors.
- Any condition that would interfere with the interpretation of study assessments or impair study participation.
- Any physical or psychological conditions or circumstance that, in the opinion of the investigator, may make a patient unsuitable for inclusion or unlikely or unable to complete the study or comply with study procedures and requirements.
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:四人间
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Active
Patients assigned will receive ISN018_055 tablets orally QD for 52 weeks
|
Dosage form: Tablets; Frequency of administration: Orally QD.
Other Names: Rentosertib
|
|
安慰剂比较:Placebo
Patients assigned will receive matching placebo orally QD for 52 weeks
|
剂型:片剂;给药频率:口服,每日一次。
|
研究衡量的是什么?
主要结果指标
结果测量 |
大体时间 |
|---|---|
|
the annual rate of forced vital capacity (FVC; mL) decline over 52 weeks.
大体时间:Weeks 0,4,12,26,39,52
|
Weeks 0,4,12,26,39,52
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
time to first occurrence of any disease progression
大体时间:up to 52 weeks
|
including 1) percent predicted forced vital capacity decrease relative to baseline greater than 10%, 2) acute exacerbation of IPF, 3) respiratory-related hospitalization, or 4) death due to respiratory
|
up to 52 weeks
|
|
change from baseline to Week 52 in quantitative computed tomography-derived lung fibrosis burden on high-resolution computed tomography(HRCT)
大体时间:week 52
|
week 52
|
|
|
change from baseline in quality of life (QoL) as measured by the patient-reported outcomes questionnaires using King's Brief Interstitial Lung Disease questionnaire (K BILD)
大体时间:Weeks 0,4,12,26,39,52
|
Weeks 0,4,12,26,39,52
|
|
|
change from baseline in QoL as measured by the patient-reported outcomes questionnaires using Living with Pulmonary Fibrosis(L-PF)
大体时间:Weeks 0,4,12,26,39,52
|
Weeks 0,4,12,26,39,52
|
|
|
change from baseline in hemoglobin-corrected diffusing capacity of the lung for carbon monoxide (DLCO) over 52 weeks
大体时间:Weeks 0, 52
|
Weeks 0, 52
|
其他结果措施
结果测量 |
大体时间 |
|---|---|
|
Incidence of treatment-emergent adverse events(Safety and Tolerability), and clinically significant changes in physical examination,vital signs,safety laboratory test
大体时间:up to 56 weeks
|
up to 56 weeks
|
|
Clinically significant changes in the 12-lead electrocardiogram(ECG) of ECG QTcF Interval
大体时间:Weeks 0,2,4,8,12,26,39,52
|
Weeks 0,2,4,8,12,26,39,52
|
|
Clinically significant changes in the 12-lead electrocardiogram(ECG) of ECG Heart Rate
大体时间:Weeks 0,2,4,8,12,26,39,52
|
Weeks 0,2,4,8,12,26,39,52
|
|
changes from baseline in serum proteome by high throughput proteomic analysis at Weeks 12, 26, and 52
大体时间:weeks 0, 12 ,26, and 52
|
weeks 0, 12 ,26, and 52
|
|
changes from baseline in serum bone biomarker of procollagen 1 intact N-terminal propeptide [P1NP]
大体时间:weeks 0, 52
|
weeks 0, 52
|
|
changes from baseline in serum bone biomarker of C-terminal telopeptide [CTX]
大体时间:weeks 0, 52
|
weeks 0, 52
|
合作者和调查者
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他研究编号
- INS018-055-301
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.